BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Olanzapine (Zyprexa) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Olanzapine (Zyprexa)\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05170919-7608@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Olanzapine (Zyprexa): Phase 2 readout est. (NCT05170919)
DESCRIPTION:Olanzapine (Zyprexa)\, phase 2.\nStudy: Comparing Olanzapine an
 d Mirtazapine in the Improvement of Unintentional Weight Loss for Patients
  with Advanced Stage Cancer\nEstimated primary completion: December 2026. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/olanzapine-zyprexa#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT051709
 19
URL:https://assetmemo.bio/drug/olanzapine-zyprexa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06554613-7608@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Olanzapine (Zyprexa): Phase 2 readout est. (NCT06554613)
DESCRIPTION:Olanzapine (Zyprexa)\, phase 2.\nStudy: Olanzapine Impact on Fi
 rst-line Immunotherapy for Advanced EGFR-negative NSCLC\nEstimated primary
  completion: 1 December 2026. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/olanzapine-zyprexa#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06554613
URL:https://assetmemo.bio/drug/olanzapine-zyprexa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07633236-7608@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20261228
DTEND;VALUE=DATE:20261229
SUMMARY:Olanzapine (Zyprexa): Phase 3 readout est. (NCT07633236)
DESCRIPTION:Olanzapine (Zyprexa)\, phase 3.\nStudy: Olanzapine in the Preve
 ntion and Treatment of Anorexia-Cachexia Syndrome in Patients Receiving Ne
 oadjuvant/Preoperative Chemotherapy\nEstimated primary completion: 28 Dece
 mber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/olanzapine
 -zyprexa#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07633236
URL:https://assetmemo.bio/drug/olanzapine-zyprexa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05814640-7608@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Olanzapine (Zyprexa): Phase 1/2 readout est. (NCT05814640)
DESCRIPTION:Olanzapine (Zyprexa)\, phase 1/2.\nStudy: Sequenced Treatment A
 lternatives to Relieve Adolescent Depression (STAR-AD)\nEstimated primary 
 completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/olanzapine-zyprexa#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05814640
URL:https://assetmemo.bio/drug/olanzapine-zyprexa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06251635-7608@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Olanzapine (Zyprexa): Phase na readout est. (NCT06251635)
DESCRIPTION:Olanzapine (Zyprexa)\, phase na.\nStudy: Effects of Antipsychot
 ics on Brain Insulin Action in Females\nEstimated primary completion: 31 D
 ecember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/olanzap
 ine-zyprexa#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06251635
URL:https://assetmemo.bio/drug/olanzapine-zyprexa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03781115-7608@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20270210
DTEND;VALUE=DATE:20270211
SUMMARY:Olanzapine (Zyprexa): Phase 1 readout est. (NCT03781115)
DESCRIPTION:Olanzapine (Zyprexa)\, phase 1\, Schizophrenia.\nStudy: Proposa
 l To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia\
 nEstimated primary completion: 10 February 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/olanzapine-zyprexa#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT03781115
URL:https://assetmemo.bio/drug/olanzapine-zyprexa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06338683-7608@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20270320
DTEND;VALUE=DATE:20270321
SUMMARY:Olanzapine (Zyprexa): Phase 3 readout est. (NCT06338683)
DESCRIPTION:Olanzapine (Zyprexa)\, phase 3.\nStudy: Survival With Olanzapin
 e in Patients With Locally Advanced or Metastatic Upper Gastrointestinal a
 nd Lung Cancer\nEstimated primary completion: 20 March 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/olanzapine-zyprexa#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06338683
URL:https://assetmemo.bio/drug/olanzapine-zyprexa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06821945-7608@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Olanzapine (Zyprexa): Phase 2 readout est. (NCT06821945)
DESCRIPTION:Olanzapine (Zyprexa)\, phase 2\, Schizophrenia.\nStudy: A Clini
 cal Trial to Evaluate the Safety and Efficacy of Olanzapine Titration Sche
 dule in Patients With Schizophrenia\nEstimated primary completion: May 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/olanzapine-zyprexa
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT068
 21945
URL:https://assetmemo.bio/drug/olanzapine-zyprexa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07455955-7608@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20270603
DTEND;VALUE=DATE:20270604
SUMMARY:Olanzapine (Zyprexa): Phase 2 readout est. (NCT07455955)
DESCRIPTION:Olanzapine (Zyprexa)\, phase 2.\nStudy: Personalized Antiemetic
  Regimen According to Patients' Pharmacogenetic Profile\nEstimated primary
  completion: 3 June 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/olanzapine-zyprexa#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07455955
URL:https://assetmemo.bio/drug/olanzapine-zyprexa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05705492-7608@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Olanzapine (Zyprexa): Phase 2 readout est. (NCT05705492)
DESCRIPTION:Olanzapine (Zyprexa)\, phase 2.\nStudy: Olanzapine for the Mana
 gement of Cancer Associated Appetite Loss in Patients With Advanced Esopha
 gogastric\, Hepatopancreaticobiliary\, Colorectal or Lung Cancer\nEstimate
 d primary completion: 30 June 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/olanzapine-zyprexa#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05705492
URL:https://assetmemo.bio/drug/olanzapine-zyprexa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07662200-7608@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Olanzapine (Zyprexa): Phase 1 readout est. (NCT07662200)
DESCRIPTION:Olanzapine (Zyprexa)\, phase 1.\nStudy: A Simplified Regimen to
  Prevent Nausea and Vomiting Using Netupitant/Palonosetron in Germ Cell Ca
 ncer Patients Receiving Chemotherapy\nEstimated primary completion: August
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/olanzapine-zyp
 rexa#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07662200
URL:https://assetmemo.bio/drug/olanzapine-zyprexa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07413809-7608@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Olanzapine (Zyprexa): Phase 3 readout est. (NCT07413809)
DESCRIPTION:Olanzapine (Zyprexa)\, phase 3.\nStudy: Prevention of Delayed C
 INV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamet
 hasone-Containing Regimen\nEstimated primary completion: September 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/olanzapine-zyprexa#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0741380
 9
URL:https://assetmemo.bio/drug/olanzapine-zyprexa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05895838-7608@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Olanzapine (Zyprexa): Phase 3 readout est. (NCT05895838)
DESCRIPTION:Olanzapine (Zyprexa)\, phase 3.\nStudy: The Danish Out-of-Hospi
 tal Cardiac Arrest Study\nEstimated primary completion: September 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/olanzapine-zyprexa#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05895838
URL:https://assetmemo.bio/drug/olanzapine-zyprexa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07743827-7608@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20270929
DTEND;VALUE=DATE:20270930
SUMMARY:Olanzapine (Zyprexa): Phase na readout est. (NCT07743827)
DESCRIPTION:Olanzapine (Zyprexa)\, phase na.\nStudy: Olanzapine Based Dexam
 ethasone-sparing Regimen for Breast Cancer Patients With Metabolic-risk Fa
 ctors\nEstimated primary completion: 29 September 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/olanzapine-zyprexa#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07743827
URL:https://assetmemo.bio/drug/olanzapine-zyprexa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04478838-7608@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Olanzapine (Zyprexa): Phase 4 readout est. (NCT04478838)
DESCRIPTION:Olanzapine (Zyprexa)\, phase 4\, Schizophrenia.\nStudy: "Extend
 ed" (Alternate Day) Antipsychotic Dosing\nEstimated primary completion: 30
  September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/olan
 zapine-zyprexa#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT04478838
URL:https://assetmemo.bio/drug/olanzapine-zyprexa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06588413-7608@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Olanzapine (Zyprexa): Phase 3 readout est. (NCT06588413)
DESCRIPTION:Olanzapine (Zyprexa)\, phase 3.\nStudy: Olanzapine 2.5 vs 5 mg 
 in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan\nEsti
 mated primary completion: October 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/olanzapine-zyprexa#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06588413
URL:https://assetmemo.bio/drug/olanzapine-zyprexa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06200181-7608@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Olanzapine (Zyprexa): Phase 3 readout est. (NCT06200181)
DESCRIPTION:Olanzapine (Zyprexa)\, phase 3.\nStudy: Effect of Olanzapine on
  Opioid Craving and Misuse Among Patients Receiving Opioids for Cancer-rel
 ated Pain: A Pilot Double-Blind\, Randomized Control Trial\nEstimated prim
 ary completion: 1 November 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/olanzapine-zyprexa#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06200181
URL:https://assetmemo.bio/drug/olanzapine-zyprexa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05635227-7608@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Olanzapine (Zyprexa): Phase na readout est. (NCT05635227)
DESCRIPTION:Olanzapine (Zyprexa)\, phase na.\nStudy: Dexamethasone\, Olanza
 pine\, Hemodynamics\, and Ventilation in Cardiac Surgery\nEstimated primar
 y completion: December 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/olanzapine-zyprexa#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT05635227
URL:https://assetmemo.bio/drug/olanzapine-zyprexa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07208305-7608@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Olanzapine (Zyprexa): Phase 3 readout est. (NCT07208305)
DESCRIPTION:Olanzapine (Zyprexa)\, phase 3.\nStudy: Olanzapine Plus Metoclo
 pramide for the Prevention of Opioid-Induced Nausea and Vomiting\nEstimate
 d primary completion: 30 December 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/olanzapine-zyprexa#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07208305
URL:https://assetmemo.bio/drug/olanzapine-zyprexa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07442890-7608@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Olanzapine (Zyprexa): Phase na readout est. (NCT07442890)
DESCRIPTION:Olanzapine (Zyprexa)\, phase na.\nStudy: A Cohort Study on the 
 Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy 
 for Lung Cancer Using Rolapitant and Palonosetron\nEstimated primary compl
 etion: 30 April 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /olanzapine-zyprexa#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07442890
URL:https://assetmemo.bio/drug/olanzapine-zyprexa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07722806-7608@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Olanzapine (Zyprexa): Phase 2 readout est. (NCT07722806)
DESCRIPTION:Olanzapine (Zyprexa)\, phase 2.\nStudy: A Nutrition and Exercis
 e Program With Olanzapine Compared to Olanzapine Alone: A Trial in Patient
 s With Advanced Tumors\nEstimated primary completion: October 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/olanzapine-zyprexa#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07722806
URL:https://assetmemo.bio/drug/olanzapine-zyprexa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07581405-7608@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Olanzapine (Zyprexa): Phase 2 readout est. (NCT07581405)
DESCRIPTION:Olanzapine (Zyprexa)\, phase 2.\nStudy: GI-05: The Impact of Ol
 anzapine Among Patients Receiving Neoadjuvant Chemotherapy for Gastric Can
 cer\nEstimated primary completion: November 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/olanzapine-zyprexa#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07581405
URL:https://assetmemo.bio/drug/olanzapine-zyprexa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06995508-7608@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20301115
DTEND;VALUE=DATE:20301116
SUMMARY:Olanzapine (Zyprexa): Phase 2 readout est. (NCT06995508)
DESCRIPTION:Olanzapine (Zyprexa)\, phase 2.\nStudy: Olanzapine for Managing
  Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation\, MAC
 RO Trial\nEstimated primary completion: 15 November 2030. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/olanzapine-zyprexa#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06995508
URL:https://assetmemo.bio/drug/olanzapine-zyprexa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07152184-7608@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20320201
DTEND;VALUE=DATE:20320202
SUMMARY:Olanzapine (Zyprexa): Phase 2 readout est. (NCT07152184)
DESCRIPTION:Olanzapine (Zyprexa)\, phase 2\, Schizophrenia.\nStudy: Study C
 omparing Antipsychotic Dose Reduction vs. Maintenance Treatment in Patient
 s With Schizophrenia Spectrum Disorder: a Personalized Medicine Approach\n
 Estimated primary completion: 1 February 2032. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/olanzapine-zyprexa#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07152184
URL:https://assetmemo.bio/drug/olanzapine-zyprexa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
